SEC Form 4 · accession 0001127602-17-005421
LEXICON PHARMACEUTICALS, INC. · LXRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Pablo Lapuerta
Officer — EVP and CMO
Period of report
Feb 9, 2017
Accepted (ET)
Feb 13, 2017 · 4:25 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001062822
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $14.44 | Feb 9, 2017 | A | 41,370 | A | — | Feb 9, 2027 | Common Stock | 41,370 | 41,370 | D |
| Restricted Stock Units (Phantom Stock)F2,F3 | — | Feb 9, 2017 | A | 10,340 | A | — | — | Common Stock | 10,340 | 10,340 | D |
Explanation of responses
- F1Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant (2/9/2018) and vests 1/48th per month for each month of service thereafter
- F2Each restricted stock unit represents a contingent right to receive one share of common stock.
- F3Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2018 and vest an additional 25% on February 28 of each of the three succeeding years thereafter.